Altasciences has acquired WCCT Global, an early stage clinical research organization (CRO) based in Southern California, for an undisclosed price.

The Canada-based mid-size CRO/CDMO said that the acquisition will complement its existing clinical operations in Montreal and Kansas City, while being in close proximity to its preclinical facility in Washington State.

Steve Mason – Co-Chief Operating Officer at Altasciences said: “This acquisition expands Altasciences’ footprint by providing Phase I and II clinical pharmacology services on the West Coast, and adds 180 beds to our current 400-bed offering. Furthermore, it allows us to enhance our capabilities with expertise in ethnobridging and other specialty areas for hard-to-recruit study populations.”

Established in 1998, WCCT Global is said to have carried out more than 600 Phase I studies.

Gregory Hanson – Executive Chairman of WCCT Global said: “Joining the Altasciences team will enhance our offering while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients.”

  Altasciences, California, Gregory Hanson, Steve Mason, USA, WCCT Global